CA2270913C - Recepteur tr2 du facteur de necrose tumorale chez l'homme - Google Patents

Recepteur tr2 du facteur de necrose tumorale chez l'homme Download PDF

Info

Publication number
CA2270913C
CA2270913C CA2270913A CA2270913A CA2270913C CA 2270913 C CA2270913 C CA 2270913C CA 2270913 A CA2270913 A CA 2270913A CA 2270913 A CA2270913 A CA 2270913A CA 2270913 C CA2270913 C CA 2270913C
Authority
CA
Canada
Prior art keywords
amino acid
seq
receptor
polypeptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2270913A
Other languages
English (en)
Other versions
CA2270913A1 (fr
Inventor
Jian Ni
Craig A. Rosen
Reiner L. Gentz
Sally Doreen Patricia Lyn
Mark Robert Hurle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
SmithKline Beecham Corp
Original Assignee
Human Genome Sciences Inc
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, SmithKline Beecham Corp filed Critical Human Genome Sciences Inc
Publication of CA2270913A1 publication Critical patent/CA2270913A1/fr
Application granted granted Critical
Publication of CA2270913C publication Critical patent/CA2270913C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne de nouveaux membres de la famille des récepteurs du facteur de nécrose tumorale. L'invention concerne des molécules isolées d'acide nucléique codant un récepteur TR2 humain et deux variantes épissées dudit récepteur. L'invention concerne aussi des polypeptides TR2, ainsi que des vecteurs, cellules hôtes et procédés de recombinaison permettant de produire lesdits éléments. L'invention concerne également des méthodes de sélection permettant d'identifier des agonistes et antagonistes de l'activité du récepteur TR2. L'invention concerne en outre des méthodes diagnostiques pour dépister des pathologies liées à l'expression aberrante de récepteurs TR2, ainsi que des méthodes thérapeutiques pour traiter des pathologies liées à une prolifération ou différenciation aberrante de cellules exprimant des récepteurs TR2.
CA2270913A 1996-10-30 1996-10-30 Recepteur tr2 du facteur de necrose tumorale chez l'homme Expired - Fee Related CA2270913C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/018540 WO1998018824A1 (fr) 1996-10-30 1996-10-30 Recepteur tr2 du facteur de necrose tumorale chez l'homme

Publications (2)

Publication Number Publication Date
CA2270913A1 CA2270913A1 (fr) 1998-05-07
CA2270913C true CA2270913C (fr) 2011-05-24

Family

ID=22256163

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2270913A Expired - Fee Related CA2270913C (fr) 1996-10-30 1996-10-30 Recepteur tr2 du facteur de necrose tumorale chez l'homme

Country Status (4)

Country Link
EP (1) EP0961782A4 (fr)
JP (1) JP2001502912A (fr)
CA (1) CA2270913C (fr)
WO (1) WO1998018824A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US6291207B1 (en) 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6346388B1 (en) 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
US6287808B1 (en) 1998-09-03 2001-09-11 Millennium Pharmaceuticals, Inc. Molecules of the herpesvirus-entry-mediator-related protein family and uses thereof
WO2000014230A1 (fr) * 1998-09-03 2000-03-16 Millennium Pharmaceuticals, Inc. Nouvelles molecules de la famille des proteines associees au mediateur d'entree du virus de l'herpes et leurs applications
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
CA2399388A1 (fr) 2000-02-11 2001-08-16 Michael J. Lenardo Identification d'un nouveau domaine dans la famille des recepteurs du facteur de necrose tumorale mediant l'assemblage et la fonction du recepteur de pre-ligand
WO2001079496A2 (fr) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand pour mediateur d'entree du virus herpes simplex et procedes de mise en oeuvre
DE60143231D1 (de) * 2000-04-12 2010-11-18 Jolla Inst Allergy Immunolog Ligand des zelleintritt-vermittelnden Proteins von Herpes Simplex und Methoden zu dessen Verwendungen
US20040235173A1 (en) * 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393438B1 (fr) * 1989-04-21 2005-02-16 Amgen Inc. Récepteur du TNF, protéine liant le TNF at ADN codant pour ceux-ci
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5464938A (en) * 1990-04-09 1995-11-07 Immunex Corporation Isolated viral protein TNF antagonists
EP0822984A4 (fr) * 1995-04-27 2000-05-03 Human Genome Sciences Inc Recepteurs du facteur de necrose tumorale chez l'homme

Also Published As

Publication number Publication date
WO1998018824A1 (fr) 1998-05-07
EP0961782A4 (fr) 2003-07-16
CA2270913A1 (fr) 1998-05-07
JP2001502912A (ja) 2001-03-06
WO1998018824A9 (fr) 1999-09-30
EP0961782A1 (fr) 1999-12-08

Similar Documents

Publication Publication Date Title
EP0970213B1 (fr) Recepteur 5 contenant un domaine de mort
US6342363B1 (en) Death domain containing receptor 4 nucleic acids and methods
WO1998030693A9 (fr) Recepteur 5 du facteur de necrose tumorale
CA2292790A1 (fr) Recepteur tr10 du facteur de necrose tumorale humain
CA2270913C (fr) Recepteur tr2 du facteur de necrose tumorale chez l'homme
US20020127637A1 (en) Human tumor necrosis factor receptor-like protein 8
US7910321B2 (en) Methods of determining the level of human tumor necrosis factor receptor-like 2
EP1788086A1 (fr) Récepteur 5 contenant un domaine de mort
AU2006246525A1 (en) Death Domain Containing Receptor 5
MXPA99008486A (en) Death domain containing receptor 5

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151030